Nanomedicine Strategies for Brain-targeted Therapy in Neurological Disorders

Neurological problems are among the world's most significant health issues. Many conditions are considered incurable because current treatments cannot effectively cross the Blood-Brain Barrier (BBB) to exert pharmacological effects. Nanomedicine utilizing various nanoparticles offers a distinct therapeutic approach to bypass the BBB and address the complex nature of these illnesses.

This review explores different nanocarrier systems-including lipid-based, polymeric, inorganic, and biological systems-that act as molecular vehicles that transport medications across the BBB by either disrupting the barrier or facilitating transcytosis.

The study highlights the clinical relevance of nanomedicine for treating neurological disorders, focusing on specific BBB penetration mechanisms, including receptor-mediated transcytosis, peptide-based strategies, and stimuli-responsive systems. Furthermore, it examines the application of nanoparticles as theranostics and in developing precision medicine.

Nanocarrier systems have shown immense effectiveness in Central Nervous System (CNS) applications. However, despite the promising effectiveness of nanomedicine in treating neurological disorders, further study remains crucial to thoroughly evaluate the long-term toxicity and complications associated with their clinical use.

Nanoparticles represent a highly effective strategy for overcoming BBB limitations and improving medication delivery. While they hold great potential for precision medicine and targeted neurological therapies, addressing long-term safety and toxicity is a mandatory requirement before widespread clinical implementation.

Abstract from PubMed (PMID 42983926). This entry was added automatically by our daily literature monitor because it matches the topics we follow; read the full paper at the original source.